1999 to 2017 Saw Drop in IBD Hospitalization Rate for Whites

THURSDAY, Dec. 12, 2019 -- From 1999 to 2017, the hospitalization rate for Crohn disease and ulcerative colitis decreased among non-Hispanic white Medicare beneficiaries aged ≥65 years, but not among non-Hispanic blacks, according to research...
Source: Drugs.com - Pharma News - Category: Pharmaceuticals Source Type: news

Related Links:

In conclusion, reduced DJ-1 expression promotes inflammation and IEC apoptosis via p53 in colitis, suggesting that the modulation of DJ-1 expression may be a potential therapeutic strategy for managing colitis.
Source: Journal of Biological Chemistry - Category: Chemistry Authors: Tags: Molecular Bases of Disease Source Type: research
The long-hyped redefinition of healthcare through wearable tech has been … well, long hyped. Early projects, such as Apple HealthKit and Fitbit, were undoubtably important in redefining ‘the possible’ but they haven’t yet achieved transformative application.  Much has been written on why the philosophy that has driven the astonishing success of consumer technology doesn ’t translate to healthcare and when we look at the state of innovation in 2020, many of these structural issues remain.   As Emily Cerciello, Associate Director, Digital Health and Engagement at the Crohn's...
Source: EyeForPharma - Category: Pharmaceuticals Authors: Source Type: news
(Scripps Research Institute) The US Food and Drug Administration has approved ozanimod, an immune-modulating therapy invented at Scripps Research, for the treatment of adults with relapsing forms of multiple sclerosis. The drug is also in advanced clinical development for adults and children with moderate-to-severe ulcerative colitis and Crohn's disease.
Source: EurekAlert! - Medicine and Health - Category: International Medicine & Public Health Source Type: news
Inflammatory bowel disease (IBD), which comprises ulcerative colitis and Crohn's disease, is an immune-mediated, chronic-relapsing, disabling disorder which is associated with increased mortality and poor patients' quality of life. Patients with IBD are at increased risk of infections for many reasons. In fact, IBD often requires a lifelong immunosuppressive and/or biologic therapy, both commonly associated with respiratory and opportunistic infections, but also gastrointestinal, urinary tract infections, and sepsis. Moreover, impaired spleen function has been found in a considerable proportion of IBD patients, further inc...
Source: Frontiers in Immunology - Category: Allergy & Immunology Source Type: research
Source: Clinical Epidemiology - Category: Epidemiology Tags: Clinical Epidemiology Source Type: research
Authors: Jarmakiewicz-Czaja S, PiÄ…tek D, Filip R Abstract Inflammatory bowel diseases is a group of inflammatory diseases. The pathogenesis of diseases is multifactorial, which may include a Western-type diet. Diseases occur with periods of recurrence and remission. Many factors can have a beneficial effect on reducing the frequency of recurrence and prolonging the remission period. Such ingredients include dietary fibre, mono- and polyunsaturated fatty acids, certain vitamins (D, C, and E), flavonoids, and minerals such as zinc and selenium. Properly selected nutrition might be an integral part of the treatment o...
Source: Journal of Nutrition and Metabolism - Category: Nutrition Tags: J Nutr Metab Source Type: research
Conclusions: High correlations were found between ADL serum concentrations obtained through conventional venipuncture and DBSs, which indicates that this home-based test can facilitate therapeutic drug monitoring–based ADL dose adjustments in daily practice.
Source: Therapeutic Drug Monitoring - Category: Drugs & Pharmacology Tags: Original Article Source Type: research
Abstract Inflammatory Bowel Disease (IBD) is an umbrella term used to describe disorders that involves Crohn's disease (CD) ulcerative colitis (UC) and pouchitis. The disease occurrence is more prevalent in working group population which not only hampers the well being of an individual but also have negative economical impact on society. The current drug regime used therapy is very costly owing to chronic nature of the disease leading to several side effects. The condition gets more aggravated due to lower concentration of drug at desired site. Therefore, in present scenario, a therapy is needed which can maximize...
Source: Current Topics in Medicinal Chemistry - Category: Chemistry Authors: Tags: Curr Top Med Chem Source Type: research
In this study, we found elements supporting a polygenic background, with frequent variants, among the Mestizo population, and the colonic mucosal enrichment of Bacteroides, Alteromonas, Neisseria, Streptococcus, and Microbacterium, may serve as a hallmark for IBS.
Source: Frontiers in cellular and infection microbiology - Category: Microbiology Source Type: research
Abstract BACKGROUND: In infliximab (IFX) treatment for Crohn's disease (CD) and ulcerative colitis (UC), it is difficult to predict treatment failure during the induction phase. In the present study for optimal IFX treatment, we attempted to estimate serum IFX concentration and clinical response in individual patients during the induction phase to predict the indication of therapeutic effect and the possibility of treatment failure in the maintenance phase. METHODS: We estimated pharmacokinetic and pharmacodynamic (PK/PD) parameters and predicted the serum IFX concentration and clinical response using a PK/PD...
Source: European Journal of Pharmaceutical Sciences - Category: Drugs & Pharmacology Authors: Tags: Eur J Pharm Sci Source Type: research
More News: Crohn's Disease | Inflammatory Bowel Disease | Medicare | Pharmaceuticals | Ulcerative Colitis